Description: The HIB19 monoclonal antibody reacts with human CD19, a 95 kDa transmembrane glycoprotein. CD19 is expressed by B cells during all stages of development excluding the terminally differentiated plasma cells. Follicular dendritic cells also express CD19. Together CD21, CD81, Leu13, MHC class II, and CD19 form a multimolecular complex that associates with BCR. Signaling through CD19 induces tyrosine phosphorylation, calcium flux and proliferation of B cells. The SJ25C1 antibody and the HIB19 monoclonal antibody recognize overlapping epitopes.

Applications Reported: This HIB19 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This HIB19 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Alexa Fluor® 700 emits at 723 nm and can be excited with the red laser (633 nm). Most instruments will require a 685 LP mirror and 710/20 filter. Please make sure that your instrument is capable of detecting this fluorochrome.

Excitation: 633-647 nm; Emission: 723 nm; Laser: Red Laser.

Filtration: 0.2 µm post-manufacturing filtered.

CD19 Antibody (56-0199-41) in Flow

Staining of normal human peripheral blood cells with Anti-Human CD3 PE (Product # 12-0037-42) and Mouse IgG1 K Isotype Control Alexa Fluor® 700 (Product # 56-4714-80) (left) or Anti-Human CD19 Alexa Fluor® 700 (right). Cells in the lymphocyte gate were used for analysis.

Booster dose after 10 years is recommended following 17DD-YF primary vaccination.

"56019942 was used in flow cytometry to assess the efficacy of a single vaccination of the Yellow Fever vaccine"

Authors Campi-Azevedo AC,Costa-Pereira C,Antonelli LR,Fonseca CT,Teixeira-Carvalho A,Villela-Rezende G,Santos RA,Batista MA,Campos FM,Pacheco-Porto L,Melo Júnior OA,Hossell DM,Coelho-dos-Reis JG,Peruhype-Magalhães V,Costa-Silva MF,de Oliveira JG,Farias RH,Noronha TG,Lemos JA,von Doellinger Vdos R,Simões M,de Souza MM,Malaquias LC,Persi HR,Pereira JM,Martins JA,Dornelas-Ribeiro M,Vinhas Ade A,Alves TR,Maia Mde L,Freire Mda S,Martins Rde M,Homma A,Romano AP,Domingues CM,Tauil PL,Vasconcelos PF,Rios M,Caldas IR,Camacho LA,Martins-Filho OA